Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 4,807 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Not applicable Interventional Results available

The Effect of Omalizumab on Responses to Cat Allergen Challenge

NCT00604786
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
omalizumab, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
Biological · Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
119
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity

NCT01691560
View directory record Official record
Conditions
Dentine Hypersensitivity
Interventions
5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice, 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice, Sodium monofluorophosphate dentifrice, Sodium fluoride dentifrice
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 27, 2026, 12:51 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

NCT04410523
View directory record Official record
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 27, 2026, 12:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

NCT02697227
View directory record Official record
Conditions
Cigarette Smoker, Tobacco Use Disorder
Interventions
Behavioral Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Smoking Cessation Intervention
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Phase 1 Interventional

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

NCT04514159
View directory record Official record
Conditions
Breast Cancer
Interventions
ZN-c5, Abemaciclib
Drug
Lead sponsor
Zeno Alpha Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Gilbert, Arizona • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Asthma and Pest Control Study: Demonstrating Return-on-Investment for In-Home Pest Control for Children With Persistent Asthma

NCT02700542
View directory record Official record
Conditions
Asthma
Interventions
Integrated Pest Management
Other
Lead sponsor
New York City Department of Health and Mental Hygiene
Government
Eligibility
5 Years to 12 Years
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 27, 2026, 12:51 PM EDT
Terminated Not applicable Interventional Results available

Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine

NCT01942486
View directory record Official record
Conditions
Migraine Disorders, Photophobia
Interventions
Investigational Coating
Device
Lead sponsor
University of Utah
Other
Eligibility
7 Years to 18 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

NCT00163527
View directory record Official record
Conditions
Asthma
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 70 Years
Enrollment
2,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cities in Georgia, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Not applicable Interventional

Increasing Adherence to Asthma Medication in Urban Teens

NCT00269282
View directory record Official record
Conditions
Asthma
Interventions
Self-Management Training, Motivational Interviewing (MI)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years to 15 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

NCT01703559
View directory record Official record
Conditions
Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 27, 2026, 12:51 PM EDT
Active, not recruiting Phase 2 Interventional

Pramipexole to Enhance Social Connections

NCT06269146
View directory record Official record
Conditions
Anxiety Disorders, Anxiety, Depression, Social Disconnection
Interventions
Pramipexole Pill, Placebo Pill
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal in ICU Setting

NCT03702283
View directory record Official record
Conditions
Penicillin Allergy
Interventions
Penicillin Allergic Risk Stratification Best Practice Alert
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Phase 2 Interventional

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

NCT01189396
View directory record Official record
Conditions
Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
A006, Placebo DPI, Proventil-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Medford, Oregon • Portland, Oregon • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 12:51 PM EDT
Terminated Phase 2 Interventional

Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

NCT01103037
View directory record Official record
Conditions
Asthma
Interventions
QAV680, QAV680 Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Cypress, California • Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Phase 3 Interventional Results available

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

NCT02483975
View directory record Official record
Conditions
Asthma
Interventions
FF, Placebo, Montelukast, Albuterol/Salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Phase 2Phase 3 Interventional

Improving the Quality of Asthma Care Using the Internet

NCT00921401
View directory record Official record
Conditions
Asthma
Interventions
Asthma Feedback
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 60 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 27, 2026, 12:51 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluating the Effects of Cleansers on the Skin

NCT03188653
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CeraVe® Eczema Soothing Body Wash, Cetaphil® RestoraDerm® Eczema Calming Body Wash, Dove® Sensitive Skin Body Wash, Eucerin® Skin Calming Body Wash, Aveeno® Skin Relief Body Wash, MooGoo® Milk Wash, Free & Clear Liquid Cleanser
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 27, 2026, 12:51 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

NCT07441395
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
Interventions
Soquelitinib, Placebo
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 27, 2026, 12:51 PM EDT
Withdrawn Phase 3 Interventional

Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment

NCT00011128
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral Treatment Interruption
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

NCT01469767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide cream
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 27, 2026, 12:51 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults

NCT01737892
View directory record Official record
Conditions
Asthma
Interventions
Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation, Arm C-Epinephrine Inhalation Aerosol CFC
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 27, 2026, 12:51 PM EDT
Completed No phase listed Observational

Bronchial Thermoplasty 10+ Year Study

NCT03243292
View directory record Official record
Conditions
Asthma
Interventions
Bronchial Thermoplasty
Other
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Los Angeles, California • Detroit, Michigan • Saint Paul, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 27, 2026, 12:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions

NCT01659931
View directory record Official record
Conditions
Asthma
Interventions
Montelukast, Singulair
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 27, 2026, 12:51 PM EDT